Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,088,425
  • Shares Outstanding, K 347,910
  • Annual Sales, $ 9,674 M
  • Annual Income, $ -2,409,000 K
  • 36-Month Beta -0.35
  • Price/Sales 0.63
  • Price/Cash Flow 1.25
  • Price/Book 1.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.95 +11.79%
on 07/07/17
18.25 -2.30%
on 06/29/17
+2.03 (+12.85%)
since 06/23/17
3-Month
9.01 +97.89%
on 04/26/17
18.25 -2.30%
on 06/29/17
+8.81 (+97.67%)
since 04/25/17
52-Week
8.31 +114.56%
on 04/24/17
32.75 -45.56%
on 08/24/16
-5.02 (-21.97%)
since 07/25/16

Most Recent Stories

More News
Daily Technical Summary Reports on Healthcare Stocks -- Valeant Pharma, Palatin Technologies, AMAG Pharma, and IDEXX Labs

If you want a Stock Review on VRX, PTN, AMAG, or IDXX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market today, DailyStockTracker.com...

SCHW : 42.97 (+2.41%)
IDXX : 166.30 (-2.28%)
PTN : 0.45 (+1.36%)
AMAG : 20.20 (+1.76%)
VRX : 17.83 (+1.65%)
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

ENZ : 11.24 (-0.53%)
EXEL : 27.65 (-1.64%)
VRX : 17.83 (+1.65%)
SNY : 48.10 (+0.82%)
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

ANIK : 48.30 (+2.01%)
FLXN : 23.95 (-2.28%)
RXDX : 9.05 (-3.21%)
VRX : 17.83 (+1.65%)
4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings

Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.

ANIK : 48.30 (+2.01%)
JNJ : 131.92 (-0.82%)
NVS : 84.27 (-0.02%)
FLXN : 23.95 (-2.28%)
RXDX : 9.05 (-3.21%)
VRX : 17.83 (+1.65%)
Valeant Agrees To Sell Obagi Medical Products Business

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that certain affiliates of the Company have entered into an agreement to sell its Obagi...

VRX.TO : 22.33 (+1.92%)
VRX : 17.83 (+1.65%)
Valeant redeems remaining USD500m outstanding senior notes

Pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSX:VRX) disclosed on Thursday that it will redeem the remaining USD500m aggregate principal amount of its outstanding 6.75%...

VRX.TO : 22.33 (+1.92%)
VRX : 17.83 (+1.65%)
Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018

Upon Redemption, Valeant's Debt Reduction Will Total More than $4.8 Billion Since the End of First-Quarter 2016

VRX.TO : 22.33 (+1.92%)
VRX : 17.83 (+1.65%)
Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018

Upon Redemption, Valeant's Debt Reduction Will Total More than $4.8 Billion Since the End of First-Quarter 2016

VRX.TO : 22.33 (+1.92%)
VRX : 17.83 (+1.65%)
Featured Company News - Valeant Pharma Pays Off $811 Million in Terms Loans

LONDON, UK / ACCESSWIRE / July 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant Pharmaceuticals International, Inc. (NYSE: VRX), following...

VRX : 17.83 (+1.65%)
Allergan Reports Positive New Data on Irritable Bowl Drug

Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel...

IRWD : 17.04 (-0.41%)
AGN : 254.83 (+0.52%)
VRX : 17.83 (+1.65%)
SGYP : 4.24 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Support & Resistance

2nd Resistance Point 17.82
1st Resistance Point 17.68
Last Price 17.82
1st Support Level 17.31
2nd Support Level 17.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.